BioXcel Therapeutics, Inc. — Operating Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/edd47281-6bb8-45e8-a059-0bbe6c28bd97/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-50.5M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-036214 |
| FY 2024 | $-67.2M | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-003985 |
| FY 2023 | $-171.8M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-003784 |
| FY 2022 | $-159.6M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-003940 |
| FY 2021 | $-106.9M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-003335 |
| FY 2020 | $-82.3M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-002916 |
| FY 2019 | $-33.6M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-002196 |
| FY 2018 | $-20.0M | 2018-01-01 – 2018-12-31 | evidence 0001558370-19-001798 |
| FY 2017 | $-4.5M | 2017-01-01 – 2017-12-31 | evidence 0001558370-19-001798 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
BioXcel Therapeutics, Inc. — all facts · Revenue · Net Income